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Abstract 
Background: Venous thromboembolism (VTE) is a common and serious medical condition, 
which is estimably responsible for more than 300,000 hospital admissions annually in the USA. 
Pulmonary embolism (PE) is a major complication of VTE, which contributes to 12% death of 
hospitalized patients. Heparin is the most common anti-coagulant, but severe allergic reactions, 
bleeding, and thrombocytopenia limit its use. Thus, seeking a botanical, nontoxic antithrombotic 
alternative is an interesting area. Morinda citrifolia L. [noni] is a medicinal plant used in folk 
remedies by Polynesians for over 2,000 years. It has been reported to have a broad range of 
therapeutic and preventive effects. The bioactivities of NJ have been continuously discovered 
with antioxidative, anti-inflammatory, analgesic, and immune modifying activities. Our novel 
hypothesis  is  whether  NJ  has  an  anti-venous  thrombotic  effect  in  rodents.  To  examine  our 
hypothesis, this study was designed to examine the anti-thrombotic effect of NJ on the jugular 
vein thrombosis model induced by ferric chloride in SD rats.  
 
Material and Methods: NJ and placebo used in this study were donated by Morinda Holding 
Inc. NJ was formulated with grape juice and blue berry juice. Placebo was prepared by using the 
same procedure of NJ preparation, but without NJ in it. Thirty-six male SD rats were divided into 
six groups. Anti-venous thrombotic activities of 5% NJ, 10% NJ, heparin, and 10% NJ plus 
heparin were examined and compared with the positive and blank controls. Thrombosis was 
induced by application of a filter paper soaked in 50% ferric chloride on the right jugular vein. A Functional Foods in Health and Disease 2011; 9:297-309                                                                 Page 298 of 309 
 
2-cm  fragment  of  the  occluded  vein  (thrombus)  was  removed  and  weighed  after  1-hour 
maturation. Blood samples were collected for platelet count, aPTT, and PT tests.  
   
Results: The weight of a 2-cm fragment of normal jugular vein was 9.9 ± 2.1 mg, while the 
weight of the occluded vein in positive controls was 30.7 ± 12 mg [p=0.001], 24.7 ± 6.5 mg in 
heparin [p=0.16], 25.5 ± 6.5 mg in 5% NJ [P=0.15], 20.0 ± 5 mg in 10% NJ [P=0.04], and 16.1 ± 
5.0 mg in heparin plus 10% NJ [P=0.02], respectively. The activity of aPTT was significantly 
increased in heparin, 60.0 ± 10.0 sec [p=0.002] compared with 16.83 ± 4.9 sec in blank control. 
There was a significant increase in 5% NJ [34.24 ± 9.6 sec, p=0.01], a slight increase in 10% NJ 
[24.0 ± 5.4 sec, p=0.06]. The activity of PT was significantly increased in heparin group only 
[36.52 ± 3.0 sec vs 26.85 ± 0.4 sec in blank control, p=0.01). There was no significant change in 
NJ  groups.  Clearly,  the  reduced  thrombus  weight  by  heparin  may  be  partially  due  to  the 
activation of aPTT and PT. The slight inhibition of NJ on aPTT activity may explain the possible 
additive antithrombotic effect of NJ with heparin. The platelet count was slightly reduced to 
775,700 in the heparin group compared with blank control, there was no changes observed in 
other groups.  
 
Conclusion:  NJ  has  an  anti-jugular  vein  thrombotic  effect  and  a  possible  additive  
antithrombotic effect with heparin by activating aPTT without induction of thrombocytopenia. 
We wonder whether NJ has an anti-platelet function activity. The mechanisms for anti-venous 
thrombotic effects of NJ needs further study. 
 
Key words:  Morinda citrifolia L. [noni], noni juice (NJ), jugular vein thrombosis, heparin, 
antithrombosis, anticoagulant, activated partial thromboplastin time [aPTT], prothrombin time 
[PT]. 
 
Background: 
Venous  thromboembolism  (VTE)  is  a  common  and  serious  medical  condition.  It  has  been 
reported to be responsible for more than 300,000 hospital admissions per year in the United 
States [1]. Of these patients, approximately one-third present with clinical symptoms of acute 
pulmonary embolism (PE) and two-thirds with deep venous thrombosis (DVT) [2].  PE is the 
major complication of VTE, which contributes to death in about 12% of hospitalized patients in 
the USA [3]. The array of illnesses produced by VTE includes suddenly death from PE, long-
term post-thrombotic syndrome, hospitalization, complications from the anticoagulant therapy 
such  as  heparin,  and  the  psychological  impact  of  a  potentially  chronic  recurrent  illness  [4]. 
Heparin is a sulfated polysaccharide with a molecular weight range of 3,000 to 30,000 Da. It 
produces its major anticoagulant effect by inactivating thrombin and an activated clotting factor 
X through an anti-thrombin-dependent mechanism [5].  A significant therapeutic drug being used 
for DVT is unfractionated heparin and low-molecular-weight heparin [6]. Recent registries and 
cohort studies suggest that approximately 10% of all patients with acute PE die during the first 1 
to 3 months after diagnosis. Overall, 1% of all patients admitted to hospitals die of acute PE, and 
10% of all hospital deaths are PE-related. These facts emphasize the need to better apply our Functional Foods in Health and Disease 2011; 9:297-309                                                                 Page 299 of 309 
 
knowledge on the pathophysiology of the disease, recognize the determinants of death or major 
adverse events in the early phase of acute PE, and most importantly, identify those patients who 
necessitate prompt medical, surgical, or interventional treatment to restore the patency of the 
pulmonary  vasculature  [7-8].  By  inactivating  thrombin,  heparin  not  only  prevents  fibrin 
formation, but also inhibits thrombin-induced activation of platelets and clotting factors V and 
VII (9). An important limitation of unfractionated heparin is the lack of an oral formulation, and 
an unpredictable anti-coagulant effect due to variable, non-specific binding to plasma proteins 
[10]. The severe side effects include heparin-induced thrombocytopenia, severe bleeding, and 
osteopenia [11]. In addition, aspirin has also been used widely in preventing thrombosis in spite 
of its weak anti-platelet effect, adverse gastrointestinal effects, which involve tract and epigastric 
discomfort, and acute mucosal erosion with chronic peptic ulceration and bleeding [12-13]. It is 
therefore important to provide a cost-effective, nontoxic, and natural product for the prevention 
of VTE, or as an adjuvant therapy for this clinical problem. Hence, an alternative and safer anti-
platelet treatment with fewer side effects is definitely needed [14-15]. 
         Morinda citrifolia L. [noni] is a medicinal plant that has been used in folk remedies by 
Polynesians  for  over  2000  years  [16-19].  It  has  been  reported  to  have  a  broad  range  of 
therapeutic effects such as anti-oxidative, anti-inflammatory, antihistamine, antifungal, antibiotic, 
anticancer,  and  analgesic  properties  [20].    It  has  also  been  reported  to  have  antithrombotic 
properties, but the mechanism remains unknown [21]. In previous studies, it was demonstrated 
that NJ made from Tahitian noni fruits by Morinda Holding Inc. is able to inhibit inflammatory 
reactions, scavenge reactive oxygen free radicals, quench lipid hydroperoxides, and inhibit Cox-
1, Cox-2, and 5-LOX activities [22-26].  Figure 1 shows a Tahitian noni tree on the beach. This 
study examined the preventive effect of NJ and its additive and/or synergistic effect with heparin 
on  jugular  vein  thrombosis  induced  by  ferric  chloride,  as  well  as  its  possible  mechanistic 
activities.  
     
 
Figure 1.   Tahitian noni tree on the beach.   
 
      Noni (Morinda citrifolia L.) is a tropical, medicinal plant used in folk 
medicine by Polynesians for over 2,000 thousands years. It was claimed to 
have  a  variety  of  therapeutic  and  preventive  effects  in  humans.  The 
traditional uses of noni are benefit to pain managements, arthritis, diabetes, 
asthma, fractured bones, constipation, lacerations, stomach pain, fever, gout, 
cancer, gynecological problems, tonic, hypertension, cardiovascular diseases, 
tuberculosis, weakness, and allergies. In modern times, the uses of noni have 
expanded to ADD/ADHD, brain problems, endometriosis, multiple sclerosis, 
and sinus problems, etc. (25-26). Tahitian Noni® juice (TNJ) is made from 
noni fruits grown in Tahitian islands by Morinda Holding Inc. in USA and 
distributed globally. The market of various blends of noni products has been 
largely expended. The bioactivity and health benefits of noni products are 
continuously discovered and reported (27). In this study, we demonstrated 
that NJ has an antithrombotic effect on the jugular vein thrombosis induced 
by ferric chloride in SD rats.   
 
          Various animal models are available for screening the efficacy of antithrombotic agents. 
But, FeCl3 induced endothelial dysfunction, platelet activation, clotting and inconsistent blood 
flow, and intravascular thrombus formation mimics closely the human pathological condition. As 
an oxidant, FeCl3 induced intravascular thrombosis is a simple and reliable model to evaluate the Functional Foods in Health and Disease 2011; 9:297-309                                                                 Page 300 of 309 
 
efficacy of antithrombotic agents. This model has been used in various animal species including 
mice,  rats  and  guinea  pigs.  The  jugular  vein  thrombosis  was  generally  selected  for 
antithrombotic  screening  because  it  was  easily  approachable  via  a  midline  cervical  incision 
without any mortality (27).  
 
Materials and Methods: 
NJ and placebo:  Noni juice (NJ) made from noni fruits grown in Tahiti was prepared and 
kindly donated by Morinda Holding Inc [28].  NJ was formulated with grape juice and blue berry 
juice. Placebo was prepared by R & D Department of Morinda Holding Inc. by using the same 
procedure of NJ preparation, but without NJ in it. NJ used in this study was diluted into 5% NJ 
and  10% NJ with  drinking water and then put  into a clean  glass drinking bottle. The fresh 
prepared NJ and 10% placebo in positive control group was changed on the daily basis. The 
amount of the NJ and placebo consumed was recorded. Other reagents were purchased from 
Sigma Chemical Inc. SD rats were purchased from Charles River Animal Laboratory. 
   
Animals’ maintenance: Thirty-six 6-weeks old male Sprague-Dawley [SD] rats were purchased 
from Charles River Animal Laboratory [Wilmington, MA, USA]. The animals were maintained 
in accordance with the recommendation of the “Guidelines for the Care and Use of Laboratory 
Animals”. All animals were housed in a room maintained at 25
oC, and with a 12 h photoperiod. 
They were fed a laboratory chow diet and water ad libitum. The experimental design for these 
tests was approved by the Institutional Ethics Review Committee for animal experiments at the 
UIC College of Medicine at Rockford.  
Experimental design: The experimental design is schematically described in Scheme 1.   
 
Scheme 1. 
 
Scheme 1.   Time course of the experiment. Two doses of NJ were pre-administered in drinking water for 
35 days. Heparin was administrated at 0 minute for 30 min, then ferric chloride was applied onto the 
exposed jugular vein for 5 min to induce thrombosis. The thrombus was removed and weighted after 1 
hour maturation and weighted. The blood samples were collected for platelet count, aPTT, and PT tests. 
 
The  animals  in  the  blank  control  were  fed  a  laboratory  chow  diet  and  water,  without  any 
treatments, the animals in the positive control group were pretreated with 10% placebo, then 
Applied FeCl3 
0 min   30 min   35 min 
Thrombus weight 
and blood collection  
Rats sacrificed 
-35 days 
5, 10% NJ 
pretreatment 
 
 90 min  
Heparin 300 units 
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treated  with  ferric  chloride;  the  animals  in  the  heparin  groups  were  not  received  any 
pretreatments; and the pretreated rats in NJ group were supplied with 5%, 10% NJ, and the 
animals in the combination of NJ plus heparin group were received 10% NJ in drinking water for 
35 days before surgery. Phase 1 study examined the preventive effect of 5% NJ and 10% NJ in 
drinking water on thrombosis induced by ferric chloride on the right jugular vein compared to 
the blank control and positive control. Phase 2 study examined whether 10% NJ had an additive 
and/or  synergistic  antithrombotic  effect  with  heparin.  The  NJ  concentration  used  in  the 
combination treatment of Phase 2 study was determined by the effective dose of NJ that caused 
the significant thrombus weight reduction in Phase 1 study. The procedure involved in this study 
was approved by the University of Illinois’ Biologic Resource Committee [BRC]. 
 
Induction  of  jugular  vein  thrombosis: The animals were pretreated with NJ or placebo in 
drinking water for 5 weeks prior to the start of thrombosis assay. The animals in heparin group 
received  300  U/kg  intravenously  30  min  prior  to  thrombus  induction.  All  animals  were 
anesthetized with an intraperitoneal injection of pentobarbital sodium [50 mg/kg]. The right neck 
was cleaned with alcohol pads, followed by a transverse cervical incision. The internal jugular 
vein was identified and a 2-cm segment was isolated with 2-0 nylon sutures. A 5x5 mm filter 
paper soaked in ferric chloride [50% w/w] was applied to the external surface of the vein for 5 
min, and then removed as previously described [29]. The skin layer was closed with stapler and 
the animals were returned to their cages. After 1 h, the rats were re-anaesthetized and sacrificed 
by intra-cardiac puncture for blood sample collection. Blood samples were collected into specific 
plastic tubes provided by a clinical lab for platelet count, aPTT and PT tests [30]. Samples were 
immediately centrifuged at 2500 rpm for 10 min to obtain plasma and stored at  -20
oC until 
analyzed. Analysis of aPTT was performed at the University of Illinois Veterinary Diagnostic 
Laboratory, Urbana, IL, while analysis of PT and platelet count was carried out at the University 
of  Illinois  Family  Health  Center  Laboratory,  Rockford,  IL.  After  blood  collection,  the  neck 
incision was examined and the presence or absence of a thrombus was noted. The 2-cm segment 
of occluded vein [thrombus] was harvested and the wet weight was determined on an analytical 
balance. The effective dose of 10% NJ was determined in the Phase-1 study. Six animals were 
pretreated with 10% NJ for 5 weeks, and heparin 300 U/kg was administered by i.v 30 min prior 
to  thrombus  induction. The thrombus  was  induced by the same  method  applied in  Phase 1. 
Thrombus wet weight was also determined and blood samples were analyzed for platelet count, 
aPTT, and PT determinations [31-32]. 
         ANOVA tests were used in statistical evaluation of the data, which are given as mean ± SD 
and a value of p<0.05 was considered as significant [33]. 
 
Results: 
The result from this study indicated that the jugular vein thrombosis was successfully induced by 
oxidative ferric chloride compared with blank control. The weight of a 2-cm of normal jugular 
segment in untreated control was measured as 9.90 ± 2.10 mg in weight. Thrombosis were also 
successfully induced in all animals of the positive control, pre-treated groups and the frequency 
of thrombus and thrombus weight in each group are presented in Table 1.   
 Functional Foods in Health and Disease 2011; 9:297-309                                                                 Page 302 of 309 
 
Table 1. Effect of NJ and heparin on frequency and weight of thrombi induced in jugular vein of 
rats. 
Treatment  t/n  Thrombus wt [mg]            P value  
Blank control  0/6  9.90 ± 2.10    
Fecl3  6/6  30.68 ±11.98  0.001*** 
Heparin [300 U/kg] only  6/6  24.72 ± 6.50               0.16 
 5% NJ  6/6  25.52 ± 6.50               0.15 
10% NJ  6/6  20.04 ± 5.04               0.04* 
10% NJ + heparin  5/6  16.05 ± 5.02               0.02* 
               
t/n= thrombus number in 6 animals for each group. Values are reported as mean weight ± SD. Student t test (p<0.05, significant, 
p<0.01 very significant, p<0.001 extremely significant).The thrombus was successfully induced by oxidative Fecl3 on jugular 
vein compared with blank control [p<0.001]. The thrombus weight in each pre-treated group was compared with Fecl3 group. 
The thrombus weight in heparin and 5% TNJ pre-treatment groups did not show a significantly reduction, the thrombus weight in 
10% TNJ pretreated group showed a significant reduction compared with positive control. The combination group had a possible 
additive reduction of thrombi weight [p=0.02] compared with 10%NJ and heparin respectively. 
 
The thrombus weight [30.68 ± 11.98 mg] in positive control group was extremely significantly 
increased [p = 0.001] compared with 9.90 ± 2.10 mg in control. There was a significant reduction 
of the thrombus weight observed in 10% NJ group although the number of thrombus was not 
significantly changed. The thrombus weight [20.04 ± 5.04 mg] in this group was significantly 
reduced compared with positive control group [p = 0.04]. It was thus used in the combination 
group of Phase 2 study to examine a possible additive and/or synergistic effect between NJ and 
heparin. The thrombus weight in heparin group had a slight reduction [24.72 mg, P > 0.05] 
compared  with  positive  control.  The  thrombus  weight  in  the  combination  group  of  NJ  plus 
heparin  had  a  possible  additive  reduction  efficacy  [16.05  ±  5.02,  p  =  0.02]  compared  with 
positive control, there was 48% reduction. There was a 34.8% reduction in heparin group and 
19.4% reduction in 10% NJ group respectively. There was one animal without an occluded vein 
observed  in  the  combination  group.  Hence,  there  was  a  possible  additive  effect  of  the 
antithrombotic effect between NJ and heparin.    
         The histopathological examination of the jugular thrombi was performed by an experienced 
pathologist.  The results were shown in Figure 2. 
 
 
Figure 2   Anti-jugular vein thrombotic effect of heparin, TNJ, and 
their combination.  
     A.  A  thrombus  induced  by  FeCl3  in  positive  control.  Severe 
oxidative damage was observed on the venous wall and the density of 
thrombus  is  very  high.  There  was  no  space  observed  between  the 
thrombus and venous wall.   
     B.  A  thrombus  in  heparin+feCl3  group  showed  less  oxidative 
damage, thrombus with low density, and there was a space between the 
thrombus and venous wall.  
     C.  A  thrombus  in  10%  TNJ+Fecl3  group  showed  much  less 
oxidative damage, thrombus with lower density, and there is a larger 
space between thrombus and venous wall.    
     D.  A  thrombus  in  the  combination  group  of  Fecl3+TNJ+heparin 
showed a smaller thrombus, less oxidative damage, and a larger space 
between thrombus and venous wall.  In summary, heparin and TNJ 
showed  an  anti-jugular  vein  thrombosis.  An  additive  antithrombotic 
effect  between  heparin  and  TNJ  was  observed  in  the  combination 
group.    Functional Foods in Health and Disease 2011; 9:297-309                                                                 Page 303 of 309 
 
        The jugular vein thrombus was successfully induced by oxidative FeCl3 in positive control 
group. The severe oxidative damage [color in black] was observed on the venous wall and the 
density of thrombus is very high without space observed between the thrombus and venous wall 
[A].  A thrombus in heparin+FeCl3 group showed less oxidative damage, thrombus with low 
density, and there was a space observed between the thrombus and venous wall [B]. A thrombus 
in 10% NJ+Fecl3 group showed much less oxidative damage, thrombus with lower density, and 
there is a larger space between thrombus and venous wall [C]. The strong anti-oxidative and anti-
inflammatory activities of NJ may play am important role on the inhibition of venous thrombosis. 
A  thrombus  in  the  combination  group  of  NJ  plus  heparin  showed  a  smaller  thrombus,  less 
oxidative damage, and a larger space between thrombus and venous wall [D].  In summary, 
heparin and NJ showed an anti-jugular vein thrombotic effect on the jugular vein thrombosis 
induced by oxidative ferric chloride in male SD rats. A possible additive antithrombotic effect of 
NJ with heparin was also observed in the combination group.        
        The impacts of NJ, heparin, and their combination regimen on aPTT and PT activities, as 
well as platelet count were determined to explore the possible mechanism for the anti-venous 
thrombotic effect of NJ, heparin, and the combination of NJ plus heparin. The data were shown 
in Table 2. In Table 2, there was a 3.5 fold of prolonged aPTT activity in heparin group [60.00 ± 
10.0 sec, p = 0.002] compared with control [16.83 ± 4.8 sec]. A significant prolongation of aPTT 
in the 5%NJ [34.24 ± 9.6 sec, p = 0.01] and a slight prolongation of aPTT in 10% NJ [24.00 ± 
5.4 sec, p = 0.06] groups compared with control. A significant prolongation of aPTT in the 
combination of 10% NJ and heparin was also observed with a value of 40.00 ± 4.5 sec and p = 
0.01, compared with control.  
 
Table 2. Effect of NJ and heparin [300U/kg] on aPTT, PT, and platelet counts 
Treatment   aPTT [sec]         P value  PT [sec]           P value    Platelet [x10
3/µl]      P value  
Control   16.83 ± 4.9**        26.85 ± 0.4       953.5 ± 86* 
Heparin-only  60.00 ± 10.0         0.002  36.52 ± 3.0**     0.01       775.7 ± 84**            0.06 
5% NJ  34.24 ± 9.6           0.01  25.15 ± 0.6         0.06       908.5 ± 71*              0.52 
10% NJ  24.00 ± 5.4           0.06  28.18 ± 3.3**     0.21       987.6 ± 95                0.67 
10% NJ + heparin  40.00 ± 4.5           0.01                                  30.60 ± 1.6         0.04                                   943.4 ± 67                0.86 
 
n=6, except indicated in table *n = 4, **n = 3 respectively. aPTT=activated partial thromboplastin time, 
PT=prothrombin time.   
 
         The PT was very significantly prolonged in heparin group [36.52 ± 3.0 sec, p = 0.01] and 
significant prolonged in the combination groups [30.60 ± 1.6 sec, p = 0.04] compared with 
control [26.85 ± 0.4 sec], respectively. There was only marginally significant prolonged in 5% 
NJ group [25.15 ± 0.6 sec, p = 0.06] and no significant change in 10% NJ group [28.18 ± 3.3 sec, 
p = 0.21] compared with control group. Therefore, the prolongation of aPTT caused by heparin 
as well as NJ may be one of possible additive antithrombotic mechanisms. The prolongation of 
PT in combination group may be mainly caused by heparin since NJ did not show a significant 
impact on PT activity.   
         The platelet count was slightly reduced in heparin group [775.7 ± 84, p = 0.06] compared 
with control group [953.5 ± 86]. There were no changes in 5% NJ, 10% NJ, and combination 
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in combination group. Thus, NJ may help with thrombocytopenia caused by heparin. This needs 
a further study to have a conclusive result.      
 
Discussion: 
Thrombosis is a complex process involving changes in the vascular wall, platelet activation, 
adhesion and aggregation, the initiation and propagation of the coagulation cascade [34]. The 
standard therapy, heparin, offers an effective prophylaxis and treatment of deep vein thrombosis, 
but is limited by its side effects of an unpredictable anticoagulant effect due to variable non-
specific binding to plasma proteins, bleeding, heparin-induced thrombocytopenia, and osteopenia 
[35-36].  In this  preliminary study, NJ  was  demonstrated  to  be  a potential  cost-effective and 
nontoxic alternative for DVT prophylaxis and adjuvant therapy.    
         The  rat  model  described  in  the  current  study  was  designed  for  the  study  of  the 
antithrombotic prophylactic effects of NJ, rather than treatment. The study indicates NJ at 10% 
concentration had an antithrombotic effect as shown with the significant reduction in thrombus 
weight. The combination group of NJ and heparin showed that 10% NJ+heparin had a possible 
additive  antithrombotic  effect  in  ferric  chloride  induced  jugular  vein  thrombosis  model. 
Although there was a significant elevation of aPTT activity in the NJ groups, but no significant 
change  in  PT,  it  suggests  a  possible  mechanism  through  another  intrinsic  pathway  such  as 
platelet function [37]. The platelet count was slightly decreased only in heparin group and there 
were no significant change in 5% NJ, 10% NJ, as well as NJ plus heparin groups compared with 
control. NJ may provide more advantages over heparin because it is effective, natural, safe, and 
without thrombocytopenia [38]. A further study is definitely needed to examine the impacts of 
NJ on the platelet function such as platelet aggregation test as well as the impacts of NJ on the 
clotting factors. 
      The strong anti-oxidative and anti-inflammatory bioactivities of NJ may be responsible for 
the anti-venous thrombotic effect of NJ since fecl3-induced venous thrombosis are involved the 
oxidative damage and inflammatory responses caused by local application of Fecl3 on jugular 
vein.  Pretreatment  with  NJ  in  rats  may  reduce  the  thrombosis  induced  by  Fecl3.  More 
specifically, the iridoids and phenolic compounds such as scopoletin, quercetin, kaempferol, and 
rutin, etc. existed in the NJ may be the major reason for the anti-venous thrombotic activity of NJ 
[39-44].   
         The latest data from our laboratory has demonstrated that NJ has a very strong anti-PE 
effect on collagen and epinephrine induced animal PE model. NJ also has a potentiating effect on 
the anti-platelet activity of aspirin using arachidonic acid, collagen, and ADP as inducers by 
using a Chrono-Log Platelet Aggregometer tests. NJ also has a potentiating anti-PE effect of 
aspirin on the animal PE model induced by collagen and epinephrine [45]. Thus, the current data 
generated in our laboratory strongly demonstrated that NJ may become an ideal, cost-effective, 
natural, and safe alternative on the prevention and treatment of VTE, DVT, and PE in humans. 
These data will be published in independent papers. We are very confident to predict that NJ 
may become a good natural blood thinner for the prevention and treatment of heart attack and 
ischemic stroke in humans.    
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Description of additional data files:   
We have recently investigated the impacts of NJ on the platelet aggregation and pulmonary 
embolism in ICR mice, the results indicated that NJ is a potent antiplatelet aggregation and anti-
pulmonary embolism agent as well as it has an additive to synergistic effect on the anti-platelet 
and anti-pulmonary embolism activities with aspirin in ICR mice. Therefore, a warning should 
be given to patients who drink noni juice on the daily basis; their primary care physician should 
determine whether the amount of aspirin should be reduced.      
 
Conclusion: 
NJ has a strong antithrombotic effect on ferric chloride-induced jugular vein thrombosis model 
in rodents. NJ may offer an effective prophylaxis to DVT through the antioxidant and anti-
inflammatory activities. Previous studies showed NJ is a dual anti-inflammatory analgesic agent 
that improves the symptoms and the QoL of Osteoarthritis patients through inhibiting Cox-1, 
Cox-2, and 5-LO, these bioactivities of NJ may also impact on the platelet function. A further 
study to explore the mechanism of the anti-thrombotic effect of NJ is definitely needed in near 
future.  A  further  study  is  suggested  to  better  evaluate  its  antithrombotic  efficiency  and 
mechanisms of action on venous thrombosis as well as artery thrombosis. NJ may become a cost-
effective antithrombotic dietary supplement if we could provide enough scientific evidence. This 
pilot study provides us a clue for the antithrombotic activity of NJ.    
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VTE=Venous thromboembolism; PE=pulmonary embolism; DVT=deep vein thromboembolism; 
TNJ=Tahitain  Noni®  juice;  NJ=noni  juice;  SD  =  Sprague-Dawley;  aPTT=activated  partial 
thromboplastin  time;  PT=prothrombin  time;  5-LO=5-lypoxygenase;  Cox  =  cyclooxygenase; 
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